Company intelligence / Profile preview

CartiHeal

Kfar Saba, Central District, Israel

Ownership: Private
Development stage: Other

Overview

Agili-C, a bi-phasic, cell-free, off-the-shelf osteochondral scaffold, has demonstrated statistically significant improvements in pain, function, and MRI/clinical outcomes vs. standard surgical care in one of the largest clinical trials for cartilage lesions; it is CE-marked and FDA approved, available commercially as of 2023, with evidence of durable benefit across lesion sizes and mild to moderate osteoarthritis[2][7].

Therapeutic areas: Rheumatology
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Implantable Medical Devices

Partnerships

Smith & Nephew (global commercial partnership and distribution)[7]Johnson & Johnson Innovation (JJDC Inc.) (investor)[1]Peregrine Ventures (investor)[1]Elron (investor)[1]

Beyond the preview

Go deeper on CartiHeal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CartiHeal.

Explore the full profile